Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964477 | 0.96 | CD274 (0.44) | CD274PDK2MTNR1AMTNR1BPDCD1 | |
| SCHEMBL9964471 | 0.87 | CD274 (0.48) | CD274PDK2MTNR1AMTNR1BFFAR1 | |
| SCHEMBL9964459 | 0.86 | FFAR1 (0.34) | CD274PDCD1FFAR1 | |
| SCHEMBL9964457 | 0.85 | CD274 (0.34) | CD274PDCD1FFAR1SMN1; SMN2 | |
| SCHEMBL9964472 | 0.84 | CD274 (0.49) | CD274PDK2MTNR1AMTNR1BFFAR1 | |
| SCHEMBL9967031 | 0.83 | CD274 (0.44) | CD274PDCD1 | |
| SCHEMBL9964485 | 0.83 | CD274 (0.33) | CD274PDCD1FFAR1 | |
| SCHEMBL9964473 | 0.82 | CD274 (0.46) | CD274PDK2MTNR1AMTNR1BFFAR1 | |
| SCHEMBL9964480 | 0.80 | CD274 (0.46) | CD274PDK2MTNR1AMTNR1BFFAR1 | |
| SCHEMBL15080634 | 0.80 | CD274 (0.34) | CD274PDCD1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | CD274 4376/4885PDK2 3025/4885MTNR1A 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.